Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca agrees Chinese clinical pharmacology unit partnership

AstraZeneca agrees Chinese clinical pharmacology unit partnership

5th September 2007

AstraZeneca has announced that it has agreed a deal to open its first Clinical Pharmacology Unit (CPU) in China.

The partnership agreement with Peking University 3rd Hospital will see the CPU focusing on phase I clinical trials, with the planned aim of speeding up new medicine access for Chinese patients.

“AstraZeneca is committed to enhancing clinical research capabilities in China,” said David Brennan, chief executive of the firm.

“The collaboration with Peking University 3rd Hospital is a great example of AstraZeneca’s patient-oriented global strategy to strengthen our R&D [research and development] pipeline for Chinese patients.”

Mr Brennan added that the CPU has been established according to the firm’s global standards and that the partnership represents a “new and innovative operating model”.

AstraZeneca will provide personnel training, system audits and consulting services to the university hospital under the terms of the agreement, while the firm will also invest to upgrade facilities to make them suitable for clinical research.

Finally, the chief executive said that China will play an “increasingly important role” in the company’s global strategy.

AstraZeneca was formed in 1999 through the merger of Astra AB Zeneca Group.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.